LATIN AMERICA ONCOLOGY DEVICE MARKET ANALYSIS

Latin America Oncology Device Market, By Chemotherapy Administration (Gravity Chemotherapy Administration, Syringe Chemotherapy Administration, Pump Chemotherapy Administration, and Others), By Accessories and Consumables (Infusion Sets, Venous Access (Ports, and Needles), Catheter (Central venous catheter(CVC), and Peripherally inserted central catheter(PICC)), Needle Connectors, Syringe Filters, and Software), By Age Group (Pediatric (Infant (from birth to 1 year), Children ( 4 to 10 years), and Teenager/Adolescent (11 to 19 years) and Adults), By End User (Private Hospitals/Clinics (General Hospitals with Oncology Centers, Specialized Hospitals, and Specialized Clinics), Public Hospitals/ Clinics (General Hospitals with Oncology Centers, Specialized Hospitals, and Specialized Clinics), and Others (Homecare Settings, and Research Institutes)), and By Country (Brazil, Mexico, and Chile) -

Published In : Jul 2023
Code : CMI4199
Pages :175
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Latin America Oncology Device Market- Key Developments

In February 2021, Pfizer, Inc., a multinational pharmaceutical and biotechnology corporation, announced a partnership with IDA Foundation, an independent social enterprise providing essential medicines to low-and middle-income countries, to provide equitable access to quality cancer treatments in almost 70 developing countries across Latin America, Asia, Africa, and the Western Pacific region. The supply agreement means that millions more patients will now have the potential to access innovative chemotherapy medicines for multiple types of cancer.

In June 2022, DAIICHI SANKYO COMPANY, LIMITED, an innovative global healthcare company, aimed to open paths for equity and inclusion for women through the “Women Friends- Amazon “initiative to provide free breast cancer screening to women in the Amazon region of Brazil.

In May 2022, Latin America Department of Health and Human Services (HHS), announced the availability of US$ 5 million for community health centers, funded by HHS’s Health Resources and Services Administration, to increase equitable access to life-saving cancer screenings. This funding supports President Joe Biden’s Unity Agenda and his call to action on cancer screening and early detection as part of the Administration’s Cancer Moonshot initiative to end cancer as we know it.

In January 2020, the Global Cancer Program hosted the “University of California, San Francisco UCSF-Mexico Cancer Collaboration Annual Meeting" with partners from Instituto Nacional Cancerologia (INCan), Instituto Nacional de Salud Pública (INSP), and the Instituto Nacional de Medicina Genómica (INMEGEN). The UCSF-Mexico Cancer Initiative aims to strengthen regional cancer research capacity and expand the institutional cancer research portfolios and training activities of partners in Mexico. This partnership has initiated projects in colorectal cancer screening and adaptation of UCSF technologies to improve pediatric cancer diagnostics in Mexico. The partnership also recently received funding from the National Institutes of Health (NIH) to examine human papillomavirus (HPV)-linked cancers in HIV-infected populations.